Jupiter Neurosciences Inc (JUNS)

$3.05 -0.10 (-3.17%)
Market Cap 2.78M
Revenue (ttm) 20,000.00
Net Income (ttm) -8.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -43,200.00%
Debt to Equity Ratio 0.00
Volume 20,900
Avg Vol 1,222,490
Day's Range N/A - N/A
Shares Out 913,000.00
Stochastic %K 22%
Beta 1.81
Analysts Strong Buy
Price Target $25.00

Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 406 6154
Address:
1001 North US Highway 1, Suite 504 Palm Beach Gardens, Jupiter, United States
abms1001
abms1001 Sep. 10 at 1:59 PM
$JUNS going to 6
1 · Reply
abms1001
abms1001 Sep. 8 at 2:52 PM
$JUNS just move up already
0 · Reply
Specialist484
Specialist484 Sep. 8 at 1:12 PM
$JUNS i cant believe Rosen. He talks about all his experiance but has royally screwed all his shareholders, including his friends and partners.
0 · Reply
lrndhfjcj
lrndhfjcj Sep. 6 at 6:37 PM
$JUNS hope on monday comes out storng bullish news 10,15,20,25$ 💣💥🚀 if company is real otherwise $000
1 · Reply
Specialist484
Specialist484 Sep. 4 at 2:21 PM
$JUNS How will management meet the $30M market cap Nasdaq listing requirment.? Rosen did say company is looking at all options available. This may include: 1. Merger: Teaming up with another company looking to go public. 2. Buyout: Company could get bought out, although it would be in their best interest to sell after phase 2 trial results. 4. Big News: Jupiter could have news in pipeline that would increase market cap significantly. While not likemy, this is a possibility 5. Delist: Choose to delist to OTC, as this wont affect their work. In conclusion; i doubt management is thinking about shareholders. Lets hope that their interests align with our own and we stay on Nasdaq.
0 · Reply
YuenglingSwing
YuenglingSwing Sep. 3 at 11:22 PM
$JUNS need an answer by tomorrow 👀
0 · Reply
focafoca99
focafoca99 Sep. 3 at 12:17 PM
$JUNS amended its bylaws to lower the quorum to one-third of voting power.
1 · Reply
Xen_TorpedoCapital
Xen_TorpedoCapital Sep. 3 at 7:24 AM
My model is BULLISH among LOW FLOAT for today: $YYAI (13d) $JUNS (10d) $CSAI (6d) Peach: $CCHH Convexity: $NCRA PWCM Statistical Test: Y
0 · Reply
Xen_TorpedoCapital
Xen_TorpedoCapital Sep. 2 at 6:20 PM
$JUNS Bought it early today, just a small position because of my model. Any news impending? Good stock?
0 · Reply
YuenglingSwing
YuenglingSwing Sep. 1 at 6:35 PM
$JUNS zoom out on the daily, this could easy run over $40. There’s a gap fill at $60. Here’s the potential… I wouldn’t sleep on this one 👀
2 · Reply
Latest News on JUNS
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?

2026-08-21T17:01:35.000Z - 22 days ago

Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?

Jupiter Neurosciences announces pricing of $2M registered direct offering

2026-08-21T16:25:13.000Z - 22 days ago

Jupiter Neurosciences announces pricing of $2M registered direct offering

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Aug 21, 2026, 12:20 PM EDT - 22 days ago

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Inc trading resumes

2026-08-21T14:15:09.000Z - 22 days ago

Jupiter Neurosciences Inc trading resumes

Jupiter Neurosciences Inc trading halted, volatility trading pause

2026-08-21T14:05:19.000Z - 22 days ago

Jupiter Neurosciences Inc trading halted, volatility trading pause

Jupiter Neurosciences Inc trading halted, news pending

2026-08-06T23:50:29.000Z - 5 weeks ago

Jupiter Neurosciences Inc trading halted, news pending

Jupiter Neurosciences announces 1-for-75 reverse stock split

2026-08-05T13:58:47.000Z - 5 weeks ago

Jupiter Neurosciences announces 1-for-75 reverse stock split

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Aug 5, 2026, 8:00 AM EDT - 5 weeks ago

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

2026-07-23T15:10:37.000Z - 7 weeks ago

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

ATAI CMND GHRS HELP LLY NRXP

Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal

2026-07-21T18:19:53.000Z - 7 weeks ago

Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal

PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences

2026-07-21T11:15:16.000Z - 7 weeks ago

PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Jul 21, 2026, 7:13 AM EDT - 7 weeks ago

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Jul 7, 2026, 8:58 AM EDT - 2 months ago

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Jupiter Neurosciences files to sell 16M shares of common stock for holders

2026-06-26T20:35:09.000Z - 2 months ago

Jupiter Neurosciences files to sell 16M shares of common stock for holders

Jupiter Neurosciences commences patient enrollment in RESET trial

2026-05-27T12:09:17.000Z - 3 months ago

Jupiter Neurosciences commences patient enrollment in RESET trial

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

May 27, 2026, 7:30 AM EDT - 3 months ago

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

May 26, 2026, 12:00 PM EDT - 3 months ago

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

May 21, 2026, 5:15 PM EDT - 3 months ago

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences announces pricing of $2M registered direct offering

2026-05-20T18:40:09.000Z - 3 months ago

Jupiter Neurosciences announces pricing of $2M registered direct offering

Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront

2026-05-20T12:17:05.000Z - 3 months ago

Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

May 20, 2026, 7:38 AM EDT - 3 months ago

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

May 4, 2026, 11:30 AM EDT - 4 months ago

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

Apr 13, 2026, 8:00 PM EDT - 5 months ago

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

Jupiter Neurosciences to present progress at Mar-a-Lago investor dinner

2026-02-25T13:48:57.000Z - 6 months ago

Jupiter Neurosciences to present progress at Mar-a-Lago investor dinner

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

Feb 25, 2026, 8:30 AM EST - 6 months ago

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Feb 23, 2026, 9:30 AM EST - 6 months ago

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Jan 28, 2026, 6:00 AM EST - 7 months ago

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Jan 27, 2026, 10:45 AM EST - 7 months ago

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6

Dec 23, 2025, 8:00 AM EST - 8 months ago

Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6

Jupiter Neurosciences to Participate in NobleCon21

Dec 2, 2025, 4:15 PM EST - 9 months ago

Jupiter Neurosciences to Participate in NobleCon21

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Aug 19, 2025, 8:12 AM EDT - 1 year ago

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 10, 2025, 4:05 PM EDT - 1 year ago

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jun 30, 2025, 3:15 PM EDT - 1 year ago

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Feb 4, 2025, 9:25 AM EST - 1 year ago

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial

Jan 30, 2025, 8:00 AM EST - 1 year ago

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Dec 4, 2024, 4:56 PM EST - 1 year ago

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

Dec 2, 2024, 7:00 PM EST - 1 year ago

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

abms1001
abms1001 Sep. 10 at 1:59 PM
$JUNS going to 6
1 · Reply
abms1001
abms1001 Sep. 8 at 2:52 PM
$JUNS just move up already
0 · Reply
Specialist484
Specialist484 Sep. 8 at 1:12 PM
$JUNS i cant believe Rosen. He talks about all his experiance but has royally screwed all his shareholders, including his friends and partners.
0 · Reply
lrndhfjcj
lrndhfjcj Sep. 6 at 6:37 PM
$JUNS hope on monday comes out storng bullish news 10,15,20,25$ 💣💥🚀 if company is real otherwise $000
1 · Reply
Specialist484
Specialist484 Sep. 4 at 2:21 PM
$JUNS How will management meet the $30M market cap Nasdaq listing requirment.? Rosen did say company is looking at all options available. This may include: 1. Merger: Teaming up with another company looking to go public. 2. Buyout: Company could get bought out, although it would be in their best interest to sell after phase 2 trial results. 4. Big News: Jupiter could have news in pipeline that would increase market cap significantly. While not likemy, this is a possibility 5. Delist: Choose to delist to OTC, as this wont affect their work. In conclusion; i doubt management is thinking about shareholders. Lets hope that their interests align with our own and we stay on Nasdaq.
0 · Reply
YuenglingSwing
YuenglingSwing Sep. 3 at 11:22 PM
$JUNS need an answer by tomorrow 👀
0 · Reply
focafoca99
focafoca99 Sep. 3 at 12:17 PM
$JUNS amended its bylaws to lower the quorum to one-third of voting power.
1 · Reply
Xen_TorpedoCapital
Xen_TorpedoCapital Sep. 3 at 7:24 AM
My model is BULLISH among LOW FLOAT for today: $YYAI (13d) $JUNS (10d) $CSAI (6d) Peach: $CCHH Convexity: $NCRA PWCM Statistical Test: Y
0 · Reply
Xen_TorpedoCapital
Xen_TorpedoCapital Sep. 2 at 6:20 PM
$JUNS Bought it early today, just a small position because of my model. Any news impending? Good stock?
0 · Reply
YuenglingSwing
YuenglingSwing Sep. 1 at 6:35 PM
$JUNS zoom out on the daily, this could easy run over $40. There’s a gap fill at $60. Here’s the potential… I wouldn’t sleep on this one 👀
2 · Reply
YuenglingSwing
YuenglingSwing Sep. 1 at 6:27 PM
$JUNS $35M value (market cap) is the goal. How much does the MM love JUNS is the question. Will they let it run??
1 · Reply
YuenglingSwing
YuenglingSwing Sep. 1 at 6:18 PM
$JUNS gap fill at 4.10, next $5…
0 · Reply
abms1001
abms1001 Sep. 1 at 5:05 PM
$JUNS bought extra 20k I believe this will fly soon
1 · Reply
Lincolnshire
Lincolnshire Sep. 1 at 4:22 PM
$JUNS I can just log off and see those paper hands that will hold on hope until they have nothing left. This is diminishing return, just look at the history. Sell on spikes and run away.
0 · Reply
YuenglingSwing
YuenglingSwing Sep. 1 at 2:06 PM
$JUNS yall keep selling for a loss. I’ll add and hold. Massive news this week.
0 · Reply
Specialist484
Specialist484 Sep. 1 at 12:56 PM
$JUNS today would be a good day to put out some positive news
0 · Reply
lrndhfjcj
lrndhfjcj Aug. 31 at 7:52 PM
$JUNS Buy when everyone is afraid, and sell when they feel at ease. 💣💥📈$10+
0 · Reply
Beardedd
Beardedd Aug. 31 at 7:51 PM
$JUNS ah pump maybe it's been getting accumulated
0 · Reply
lecorb
lecorb Aug. 31 at 7:47 PM
$FNRG $WHLR $GCL $DAIC $JUNS Perhaps one of these will experience a major rebound after hours. 🤔
1 · Reply
lecorb
lecorb Aug. 31 at 7:19 PM
$FNRG $WHLR $GCL $DAIC $JUNS Some of the day's corpses!
0 · Reply
Jonsbr
Jonsbr Aug. 31 at 6:54 PM
$JUNS Buy when everyone is afraid, and sell when they feel at ease. That is the nature of the markets.🫢👀🔥
2 · Reply